Disorders of gastrointestinal motility are frequently seen in clinical practice. Apart from motility disorders, factors leading to lowered visceroperception thresholds are recognized as commonly ...
Gvoke VialDx is expected to be available in the third quarter of 2025. The Food and Drug Administration (FDA) has approved Gvoke VialDx ™ (glucagon) for intravenous use as a diagnostic aid during ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果